Beckman Coulter BEC Stock Purchasers File Securities Fraud Class Action Lawsuit Complaint Against Beckman Coulter Over Alleged Modifications To Troponin Test Kits.

A securities fraud class action lawsuit has been filed against Beckman Coulter, Inc. (“Beckman Coulter” or “BEC”) and certain Beckman Coulter officers and/or directors (collectively “Defendants”) in the United States District Court for the Central District of California on behalf of a class consisting of all purchasers of Beckman Coulter common stock (symbol: BEC) during the period between July 31, 2009 and July 22, 2010, inclusive (the “Class Period”), alleging that Beckman Coulter, a provider of biomedical testing instrument systems, tests and supplies for clinical laboratories worldwide, and certain of its officers and/or directors violated federal securities fraud laws by issuing false and misleading statements and failing to disclose that Beckman Coulter had made certain modifications to its troponin test kit without seeking the appropriate product clearances from the Food and Drug Administration (“FDA”) and failing to disclose the adverse impact its troponin quality and compliance issues would have on Beckman Coulter’s operations and financial results (including an alleged drop in customer retention rates in its Clinical Diagnostics segment that reportedly caused Beckman Coulter to focus more of its resources on customer retention and less on new customer additions), purportedly in violation of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, according to class action lawsuit news reports.

If You Have Thoughts On The Beckman Coulter Securities Fraud Class Action Lawsuit, Share Your Class Action Comments Below.